CKAP2L and cancer: Interestingly, this result, in contrast to the traditional chemotherapeutic agents, implies that immunotherapy may address drug insensitivity in patients with high CKAP2L expression, and CKAP2L may serve as a potential biomarker to guide the choice of cancer treatment modality.